MRVI * Stock Overview
A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.00 |
| 52 Week High | US$85.00 |
| 52 Week Low | US$81.00 |
| Beta | -0.19 |
| 11 Month Change | 0% |
| 3 Month Change | 4.94% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRVI * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MRVI * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how MRVI * performed against the MX Market.
Price Volatility
| MRVI * volatility | |
|---|---|
| MRVI * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: MRVI * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRVI *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 670 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI * fundamental statistics | |
|---|---|
| Market cap | Mex$35.96b |
| Earnings (TTM) | -Mex$2.04b |
| Revenue (TTM) | Mex$4.95b |
3.8x
P/S Ratio-9.3x
P/E RatioIs MRVI * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI * income statement (TTM) | |
|---|---|
| Revenue | US$288.95m |
| Cost of Revenue | US$148.74m |
| Gross Profit | US$140.20m |
| Other Expenses | US$259.23m |
| Earnings | -US$119.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 48.52% |
| Net Profit Margin | -41.19% |
| Debt/Equity Ratio | 68.9% |
How did MRVI * perform over the long term?
See historical performance and comparison